Skip to content
Business Times – Lifestyle
Author:
ELI LILLY AND COMPANY
Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial
May 21, 2026
Lilly to participate in Bernstein’s 42nd Annual Strategic Decisions Conference
May 18, 2026
Lilly and UNICEF collaborate to give millions of children a healthier start
May 14, 2026
Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility
May 7, 2026
Foundayo™ (orforglipron), Lilly’s new oral GLP-1 pill for weight loss, now available in the U.S.
April 9, 2026
←
Previous Page
1
…
5
6
7